Fennec Pharmaceuticals Q3 product sales rise

Fennec Pharmaceuticals

13/11/2025 21:16

Overview

Fennec Q3 2025 net product sales grew 79% yr/yr to $12.5 mln

Company achieved positive cash flow from operations, cash position rose to $22 mln

Preliminary results from Japan clinical trial expected in Q4 2025

Outlook

Preliminary results from Japan's STS-J01 trial expected in Q4 2025

Fennec to explore Japan registration and partnerships if STS-J01 results are positive

Company expects further clinical collaborations to strengthen PEDMARK's foundation

Result Drivers

PEDMARK ADOPTION - Accelerated adoption across oncology networks drove sales growth, reflecting confidence in PEDMARK's clinical value

STRATEGIC INITIATIVES - Strengthening commercial organization and balance sheet contributed to positive operational results

CLINICAL VALIDATION - Engagement with key opinion leaders and investigator-initiated studies support PEDMARK's clinical foundation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$12.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $13.00, about 40.2% above its November 12 closing price of $7.78

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nGNX4zFzcN

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)